Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction

被引：53

作者：

Heusch, G. ^{[1
]}

机构：

[1] Univ Essen Gesamthsch, Sch Med, Inst Pathophysiol, Essen, Germany

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2008年 / 155卷 / 07期

关键词：

atherosclerosis; beta-blocker; heart rate; infarct size; ivabradine; myocardial ischaemia; reperfusion; remodelling;

D O I：

10.1038/bjp.2008.347

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The bradycardic agent ivabradine has proved to be of benefit in experimental models with the end points of ischaemic myocardial blood flow and contractile function, infarct size, post-infarct remodelling and atherosclerosis. The benefits to ischaemic myocardial blood flow and contractile function are strictly heart rate dependent; those on infarct size are partly heart rate independent. The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post-infarct remodelling is entirely unclear.

引用

页码：970 / 971

页数：2

共 10 条

[1] The properties of the pacemaker current IF in human ventricular myocytes are modulated by cardiac disease [J].

Cerbai, E ;

Sartiani, L ;

DePaoli, P ;

Pino, R ;

Maccherini, M ;

Bizzarri, F ;

DiCiolla, F ;

Davoli, G ;

Sani, G ;

Mugelli, A .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (03) :441-448

[2] Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice [J].

Custodis, Florian ;

Baumhaekel, Magnus ;

Schlimmer, Nils ;

List, Franka ;

Gensch, Christoph ;

Boehm, Michael ;

Laufs, Ulrich .

CIRCULATION, 2008, 117 (18) :2377-2387

[3] Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice [J].

Drouin, A. ;

Gendron, M-E ;

Thorin, E. ;

Gillis, M-A ;

Mahlberg-Gaudin, F. ;

Tardif, J-C .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (04) :749-757

[4] ELIMINATION OF EXERCISE-INDUCED REGIONAL MYOCARDIAL DYSFUNCTION BY A BRADYCARDIAC AGENT IN DOGS WITH CHRONIC CORONARY STENOSIS [J].

GUTH, BD ;

HEUSCH, G ;

SEITELBERGER, R ;

ROSS, J .

CIRCULATION, 1987, 75 (03) :661-669

[5] Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents [J].

Heusch, G. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (08) :1589-1601

[6] α-Adrenergic coronary vasoconstriction and myocardial ischemia in humans [J].

Heusch, G ;

Baumgart, D ;

Camici, P ;

Chilian, W ;

Gregorini, L ;

Hess, O ;

Indolfi, C ;

Rimoldi, O .

CIRCULATION, 2000, 101 (06) :689-694

[7]

HEUSCH G, 2008, EUR HEART J

[8] Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations [J].

Michels, Guido ;

Brandt, Mathias C. ;

Zagidullin, Naufal ;

Khan, Ismail F. ;

Larbig, Robert ;

van Aaken, Sebastian ;

Wippermann, Jens ;

Hoppe, Uta C. .

CARDIOVASCULAR RESEARCH, 2008, 78 (03) :466-475

[9] BRADYCARDIAC AGENT UL-FS-49 ATTENUATES ISCHEMIC REGIONAL MYOCARDIAL DYSFUNCTION AND REDUCES INFARCT SIZE IN SWINE - COMPARISON WITH THE BETA-BLOCKER ATENOLOL [J].

SCHULZ, R ;

ROSE, J ;

SKYSCHALLY, A ;

HEUSCH, G .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (02) :216-228

[10]

Skyschally A, 2008, HERZ, V33, P88, DOI 10.1007/s00059-008-3101-9

← 1 →